Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation.
Hiroyuki KarasawaYota YasumizuTakeo KosakaTatsunori ShimoiMototsugu OyaPublished in: IJU case reports (2024)
The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.